Accès gratuit
Numéro
Med Sci (Paris)
Volume 27, Numéro 6-7, Juin–Juillet 2011
Page(s) 633 - 638
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2011276016
Publié en ligne 1 juillet 2011
  1. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003 ; 3 : 243-252. [CrossRef] [PubMed]
  2. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008 ; 5 : 588-599. [CrossRef] [PubMed]
  3. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. Febs J 2009 ; 276 : 6880-6904. [CrossRef] [PubMed]
  4. Soussi T. p53 Antibodies in the sera of patients with various types of cancer : a review. Cancer Res 2000 ; 60 : 1777-1788. [PubMed]
  5. Schubert U, Antón LC, Gibbs J, et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000 ; 404 : 770-774. [CrossRef] [PubMed]
  6. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997 ; 94 : 1914-1918. [CrossRef]
  7. Ulanet DB, Torbenson M, Dang CV, et al. Unique conformation of cancer autoantigen B23 in hepatoma : a mechanism for specificity in the autoimmune response. Proc Natl Acad Sci U S A 2003 ; 100 : 12361-12366. [CrossRef] [PubMed]
  8. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer 2000 ; 86 : 702-712. [CrossRef] [PubMed]
  9. Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010 ; 70 : 1306-1313. [CrossRef] [PubMed]
  10. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 2001 ; 98 : 12659-12664. [CrossRef]
  11. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003 ; 21 : 37-38. [CrossRef] [PubMed]
  12. Anderson KS, LaBaer J. The sentinel within : exploiting the immune system for cancer biomarkers. J Proteome Res 2005 ; 4 : 1123-1133. [CrossRef] [PubMed]
  13. Li Y, Karjalainen A, Koskinen H, et al. p53 autoantibodies predict subsequent development of cancer. Int J Cancer 2005 ; 114 : 157-160. [CrossRef] [PubMed]
  14. International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006 ; 355 : 1763-1771. [CrossRef] [PubMed]
  15. Madoz-Gúrpide J, Kuick R, Wang H, Misek DE, Hanash SM. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics 2008 ; 7 : 268-281. [PubMed]
  16. Chen G, Wang X, Yu J, Varambally S, et al. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 2007 ; 67 : 3461-3467. [CrossRef] [PubMed]
  17. Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer : possibilities for early detection and subsequent cure. Thorax 2008 ; 63 : 228-233. [CrossRef] [PubMed]
  18. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011 ; 22 : 383-389. [CrossRef] [PubMed]
  19. Leidinger P, Keller A, Ludwig N, et al. Toward an early diagnosis of lung cancer : an autoantibody signature for squamous cell lung carcinoma. Int J Cancer 2008 ; 123 : 1631-1636. [CrossRef] [PubMed]
  20. Leidinger P, Keller A, Heisel S, et al. Identification of lung cancer with high sensitivity, specificity by blood testing. Respir Res 2010 ; 11 : 18. [CrossRef] [PubMed]
  21. Launoy G. Epidemiology of cancers in France. Rev Prat 2010 ; 60 : 178-182. [PubMed]
  22. Desmetz C, Bascoul-Mollevi C, Rochaix P, et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009 ; 15 : 4733-4741. [CrossRef] [PubMed]
  23. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer : their use as an aid to early diagnosis. Ann Oncol 2007 ; 18 : 868-873. [CrossRef] [PubMed]
  24. Wang X, Yu J, Sreekumar A, Varambally S, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005 ; 353 : 1224-1235. [CrossRef] [PubMed]
  25. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 2007 ; 6 : 1115-1122. [CrossRef] [PubMed]
  26. Sahin U, Türeci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 199 ; 9: 709-716.
  27. Flahault A, Costagliola D. Is lung cancer screening by the helical scanner justified ? Med Sci (Paris) 2007 ; 23 : 333-334. [CrossRef] [EDP Sciences] [PubMed]
  28. Hill C. Critical interpretation of the cancer incidence increase in France. Med Sci (Paris) 2009 ; 25 : 297-299. [CrossRef] [EDP Sciences] [PubMed]
  29. Desmetz C, Mangé A, Solassol J. Comparison of proteomic strategies to identify antibodies resulting from the humoral immune response to cancer. Med Sci (Paris) 2008 ; 24 : 1071-1076. [CrossRef] [EDP Sciences] [PubMed]
  30. Julian-Reynier C. Prédisposition génétique aux cancers du sein et de l’ovaire : importance des résultats des tests. Med Sci (Paris) 2011 ; 27 : 657-661. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.